{"id":80411,"date":"2022-12-22T12:38:07","date_gmt":"2022-12-22T11:38:07","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/?p=80411"},"modified":"2023-01-18T11:25:20","modified_gmt":"2023-01-18T10:25:20","slug":"onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/","title":{"rendered":"OneChain leads the world&#8217;s first clinical trial with CAR-T technology for patients with leukaemia"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.onechaintx.com\/\" target=\"_blank\" rel=\"noopener\">OneChain Immunotherapeutics (OCI)<\/a>\u00a0has obtained authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) for the CARxALL trial, the first clinical study to evaluate a new CAR-T therapy for patients who have T-cell leukemia without therapeutic alternatives. This is the most advanced project of the spin-off, founded by Dr. Pablo Men\u00e9ndez and the <a href=\"https:\/\/www.carrerasresearch.org\/en\" target=\"_blank\" rel=\"noopener\">Josep Carreras Leukaemia Research Institute<\/a>, which develops its activity in the Barcelona Science Park under the <a href=\"https:\/\/www.pcb.ub.edu\/en\/bcn-health-booster\/\" target=\"_blank\" rel=\"noopener\">BCN Health Booster<\/a> accelerator.<\/strong><\/p>\n<p>The CARxALL trial will evaluate, for the first time, the CAR-T CD1a (OC-1) therapy. This treatment specifically targets a subtype of T-cell leukaemia, cortical T-cell acute lymphoblastic leukaemia (coT-ALL), which accounts for 30-40% of T-ALLs and has a poor prognosis in patients who do not respond to currently available treatments.<\/p>\n<p>The clinical production of the CD1a CAR-T therapy for the trial has been led by <strong>Dr. Maria Castell\u00e0<\/strong>, a doctor in the Immunology Service at the Biomedical Diagnostic Centre of Hospital Cl\u00ednic Barcelona, directed by <strong>Dr. Manel Juan<\/strong>.<\/p>\n<p>The trial will be conducted at Hospital Cl\u00ednic and Hospital Sant Joan de D\u00e9u in Barcelona, under the direction of <strong>Dr. N\u00faria Mart\u00ednez <\/strong>and<strong> Dr. Susana Rives<\/strong>, principal investigators for the study.<\/p>\n<p>It is expected to include both paediatric and adult patients without any therapeutic alternatives. Although the patients will be treated in Barcelona, patients from Spain and across Europe may join the trial.<\/p>\n<p>The group led by Dr. Pablo Men\u00e9ndez, founder of OCI and director of the Josep Carreras Institute\u2019s stem cell biology, developmental leukaemia and immunotherapy group, was the first in the world\u00a0to develop and validate a CD1a-specific CAR-T for coT-ALL.\u00a0The study, led by <strong>Dr. Diego S\u00e1nchez<\/strong> and published in the journals\u00a0<a href=\"https:\/\/ashpublications.org\/blood\/article\/133\/21\/2291\/272754\/Fratricide-resistant-CD1a-specific-CAR-T-cells-for\"><em>Blood<\/em><\/a><em>\u00a0<\/em>and the <em>Journal for ImmunoTherapy of Cancer<\/em>, has been conducted with animal models using cell lines derived from patients with coT-ALL. Preliminary results show that these CAR-T cells persist\u00a0<em>in vivo<\/em>\u00a0in the long term and retain their anti-leukaemia activity.<\/p>\n<p>The CARxALL clinical trial represents\u00a0another step towards developing adoptive cell immunotherapy, such as CAR\u2013T cell therapy,\u00a0a treatment that consists of extracting a patient\u2019s T cells (cells that protect the body from infection), modifying them in the laboratory and returning them to the patient. This modification enables the cells to attack and eliminate the receptors located in the membranes of tumour cells. With this technique, the patient\u2019s own modified cells attack the cancer cells in a directed way, without damaging healthy cells.<\/p>\n<p>OCI achieved this important milestone after being created in 2020 by <strong>Dr. Pablo Men\u00e9ndez<\/strong> and the Josep Carreras Leukaemia Research Institute, through a <a href=\"https:\/\/invivo.capital\/es\/portoflio_invivo\/onechain-immunotherapeutics\/\">round of seed capital<\/a>\u00a0amounting to 3.05 million euros provided by Invivo Ventures,\u00a0<a href=\"http:\/\/www.cdti.es\/\">CDTI-Innvierte<\/a>\u00a0and the Josep Carreras Foundation, and after receiving funding from the\u00a0<a href=\"https:\/\/www.aei.gob.es\/noticias\/agencia-estatal-investigacion-publica-convocatoria-ayudas-proyectos-colaboracion-publico\">State Research Agency<\/a>. This is a successful case of technology transfer and public-private collaboration involving recovery of public investment in research.<\/p>\n<p>According to\u00a0<strong>Dr.<\/strong>\u00a0<strong>Men\u00e9ndez<\/strong>,\u00a0\u201cDeveloping these strategies and managing all the regulatory mechanisms associated with developing a product is extremely complicated in the academic field. Therefore, OCI will enable us to carry out all the necessary steps\u00a0to ensure that our knowledge benefits patients\u201d.<\/p>\n<p><strong>Antoni Garc\u00eda Prat<\/strong>, the administrator of the Josep Carreras Foundation, added,\u00a0\u201cThe Foundation decided to support the initial investment by Invivo Ventures and CDTI as an indication of its support for translational research and the research team. It is important to keep in mind that the projects concern rare or childhood haematological tumours, or those with few therapeutic alternatives, and\u00a0that any profits generated for the Foundation will be fully invested in the fight against leukaemia, always in the best interests of patients\u201d.<\/p>\n<p><strong>Prof. Evarist Feliu<\/strong>, president of the Josep Carreras Leukaemia Research Institute\u2019s Delegate Committee, said,\u00a0\u201cImmunotherapy currently constitutes an important field for cancer treatment. Its main clinical relevance currently lies in immune system checkpoint inhibitors and adoptive therapy strategies with T cells, with more than 700 clinical trials taking place throughout the world for the treatment of malignant blood diseases and, to a lesser extent, solid tumours\u201d.<\/p>\n<p><strong>Llu\u00eds Pareras<\/strong>\u00a0and<strong>\u00a0Albert Ferrer<\/strong>, founding partners of Invivo Ventures, went on to say, \u201cOneChain is developing several programmes in the field CAR-T stemming from technology transfer. With its first programme,\u00a0OCI has demonstrated its ability to bring a product based on academic research results to clinical trial in as little as two years. In addition, it has a new allogeneic platform, a haematological tumour programme and a solid tumour programme in the pipeline\u201d.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>OneChain Immunotherapeutics (OCI)\u00a0has obtained authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) for the CARxALL trial, the first clinical study to evaluate a new CAR-T therapy for&#8230;<\/p>\n","protected":false},"author":11,"featured_media":80409,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[36],"tags":[],"class_list":["post-80411","post","type-post","status-publish","format-standard","has-post-thumbnail","category-science"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OneChain leads the world&#039;s first clinical trial with CAR-T technology for patients with leukaemia - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OneChain leads the world&#039;s first clinical trial with CAR-T technology for patients with leukaemia - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"OneChain Immunotherapeutics (OCI)\u00a0has obtained authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) for the CARxALL trial, the first clinical study to evaluate a new CAR-T therapy for...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-22T11:38:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-18T10:25:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/web_foto-de-grupo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1202\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Iuris\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Iuris\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/\"},\"author\":{\"name\":\"Iuris\",\"@id\":\"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d\"},\"headline\":\"OneChain leads the world&#8217;s first clinical trial with CAR-T technology for patients with leukaemia\",\"datePublished\":\"2022-12-22T11:38:07+00:00\",\"dateModified\":\"2023-01-18T10:25:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/\"},\"wordCount\":771,\"image\":{\"@id\":\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/web_foto-de-grupo.jpg\",\"articleSection\":[\"SCIENCE\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/\",\"url\":\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/\",\"name\":\"OneChain leads the world's first clinical trial with CAR-T technology for patients with leukaemia - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.pcb.ub.edu\/es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/web_foto-de-grupo.jpg\",\"datePublished\":\"2022-12-22T11:38:07+00:00\",\"dateModified\":\"2023-01-18T10:25:20+00:00\",\"author\":{\"@id\":\"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#primaryimage\",\"url\":\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/web_foto-de-grupo.jpg\",\"contentUrl\":\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/web_foto-de-grupo.jpg\",\"width\":1920,\"height\":1202},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.pcb.ub.edu\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OneChain leads the world&#8217;s first clinical trial with CAR-T technology for patients with leukaemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.pcb.ub.edu\/es\/#website\",\"url\":\"https:\/\/www.pcb.ub.edu\/es\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d\",\"name\":\"Iuris\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g\",\"caption\":\"Iuris\"},\"url\":\"https:\/\/www.pcb.ub.edu\/en\/author\/adminiuris\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OneChain leads the world's first clinical trial with CAR-T technology for patients with leukaemia - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/","og_locale":"en_US","og_type":"article","og_title":"OneChain leads the world's first clinical trial with CAR-T technology for patients with leukaemia - Parc Cient\u00edfic de Barcelona","og_description":"OneChain Immunotherapeutics (OCI)\u00a0has obtained authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) for the CARxALL trial, the first clinical study to evaluate a new CAR-T therapy for...","og_url":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2022-12-22T11:38:07+00:00","article_modified_time":"2023-01-18T10:25:20+00:00","og_image":[{"width":1920,"height":1202,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/web_foto-de-grupo.jpg","type":"image\/jpeg"}],"author":"Iuris","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Iuris","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/"},"author":{"name":"Iuris","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d"},"headline":"OneChain leads the world&#8217;s first clinical trial with CAR-T technology for patients with leukaemia","datePublished":"2022-12-22T11:38:07+00:00","dateModified":"2023-01-18T10:25:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/"},"wordCount":771,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/web_foto-de-grupo.jpg","articleSection":["SCIENCE"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/","url":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/","name":"OneChain leads the world's first clinical trial with CAR-T technology for patients with leukaemia - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/web_foto-de-grupo.jpg","datePublished":"2022-12-22T11:38:07+00:00","dateModified":"2023-01-18T10:25:20+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/web_foto-de-grupo.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/web_foto-de-grupo.jpg","width":1920,"height":1202},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/onechain-leads-the-worlds-first-clinical-trial-with-car-t-technology-for-patients-with-leukaemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"OneChain leads the world&#8217;s first clinical trial with CAR-T technology for patients with leukaemia"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d","name":"Iuris","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g","caption":"Iuris"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminiuris\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/80411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=80411"}],"version-history":[{"count":13,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/80411\/revisions"}],"predecessor-version":[{"id":80862,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/80411\/revisions\/80862"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/80409"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=80411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=80411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=80411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}